Injecting molecules from a sea slug that received tail shocks into one that didn’t made the recipient animal behave more cautiously.
The Scientist is bringing together a panel of experts who will share their research, summarize the state of the science, and discuss the next steps for those looking to adopt the technique.
September 8, 2017|
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology has been hailed as a breakthrough and emerged as the new face of precision medicine. Its potential as a treatment for numerous diseases, stretching from various cancer types to neurological diseases to lethal heritable disorders, has been well documented. However, efforts are ongoing that aim to clarify the complex issues surrounding the legality and ethics of genome editing for human use. For a detailed look at the progress made toward CRISPR-mediated correction of human diseases and the continuing ethics debate, The Scientist is bringing together a panel of experts who will share their research, summarize the state of the science, and discuss the next steps for those looking to adopt the technique. Attendees will have the opportunity to interact with experts, ask questions, and seek advice on topics related to their research.
Topics to be covered:
Meet the Speakers:
Dana Carroll, PhD
Distinguished Professor, Department of Biochemistry
University of Utah School of Medicine
James Dahlman, PhD
Assistant Professor, Department of Biomedical Engineering
Georgia Institute of Technology and Emory School of Medicine